Header Ads Widget

Ticker

6/recent/ticker-posts

Infection Prevention and Control Market Research Report: Market Size, Industry Outlook, Market Forecast, Demand Analysis, Market Share, Market Report 2020-2025

Infection prevention & Control Market - Forecast (2020 - 2025)

Infection Prevention and Control Market size is anticipated to reach $201.71 billion by 2025, growing at a CAGR of 3.7% during the forecast period 2020-2025. With Infections and Infectious Diseases taking an extraordinary turn in all countries an incorporated methodology is required to decrease the burden thereby uniting treatment of patients and health promotions. Trends towards a fundamental understanding of the study of disease transmission; risk factors that expand persistent powerlessness to disease; and the practices, techniques and medications that may bring about contamination have clearly benefited Infection Prevention and Control market. 

Key Takeaways

  • North America region is anticipated to grasp 44.8% share during the forecast period.
  • The concern for cleanliness and hygienic of all workers in keeping the environment neat; prevents the workers as well as the patients from various Health Associated Infections (HAI).
  • Control from various types of cross-infections in hospitals and clinics also there has been a growth of Personal Protective Equipment’s market globally.
Image: Freepik.com | Infection_Prevention_and_Control_Market_Research_Report_Size_Industry_Outlook_Forecast_Demand_Analysis_Share_Report_2020_2025

Infection Type - Segment Analysis

In 2019, Bacterial Infections segment dominated the Infection prevention and control market. The advancements in technologies, increasing of consumer wealth due to population growth coupled with the growing needs of the people towards the healthcare settings will drive the market in this region. The prevalent burden of healthcare-associated infection is increasing significantly higher in low- and middle-income than in high-income countries, and mostly to the patients admitted to intensive care units and in neonates with a weaker immune system.

Anti-Microbial Drug Type - Segment Analysis

In 2019, the anti-bacterial drug segment dominated the Infection prevention and control market. The different classes of antibacterial drugs that are currently being in the market all have diverse performance profiles, but they share a common characteristic under some useful set of condition of being lethal to micro bacteria. Regardless of numerous genuine drawbacks, the different formulations that keep up their business sector development rates are evidence of the interest in antimicrobial products.

Product & Service Equipment - Segment Analysis

The Personal protective equipment segment of Infection protection and control market is anticipated to hold a major share of IP&C Market followed by Disinfectants and Sterilization. With the growth in prevention and control concerns of various Health Associated Infections, Personal Protective Equipment’s accounted for 31% of the Global IP&C Market shares. To control various types of cross-infections in hospitals and clinics also there has been a growth of Personal Protective Equipment’s market globally. Demand for better quality care in hospitals and other healthcare establishments is forcing the hospitals to invest in quality medical protective wear and other accessories has also acted as a key factor in the growth of this segment.

By End-User - Segment Analysis

At the end-user, Manufacturing Units of Infection prevention and control market will continue to dominate the IP&C Market during the forecast period. The concern for cleanliness and hygienic of all workers helps in keeping the environment neat and prevent the workers as well as the patients from various Health Associated Infections.

By Geography - Segment Analysis

North America region is anticipated to grasp 44.8% share during the forecast period. With the increase in the number of death due to Antibiotic-resistant infections, by contrast it is anticipated that there will be a growth in IP&C Market in the regions of North America and Europe. With development, rising economies, changing lifestyle and emerging microbial threat in the APAC region will act as major key factors for enhancement of the global IP&C Market. 

Drivers – Infection Prevention and Control Market

Increase In Incidence Of Hospital Acquired Infections (HAI)

Hospital Acquired Infections (HAI) are infections that patients come across as a result of medical services intervention to treat other conditions. The increasing rate of Hospital Acquired Infection has led to an increase in the demand for infection prevention and control products such as syringes, gloves, disinfectants, disposable needles and so on. The advent of various infectious disease testing kits, proper means of sanitation method has also provided a wide contribution towards the increasing sales of the product in the global market.

Challenges – Infection Prevention and Control Market

Low Level Of Vaccination Among Healthcare Workers

Healthcare workers play an important role in advocating seasonal influenza vaccination to their patients. Most health care workers accept that they are healthy and in this manner will get no profit from vaccination or that the danger of unfriendly occasions after vaccination exceeds the profits. On the other hand, they are basically uninformed of the proposals for yearly flu inoculation. Vaccination for health care workers can possibly profit health care experts, their patients, and their families by lessening the transmission of the microorganisms in the health care setting.

Infection Prevention and Control Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Infection Prevention and Control market. In 2019, Infection Prevention and Control market share is fragmented by the top ten players present in the market. 

Infection Prevention and Control market top 10 companies are Abbott, Ansell Ltd., Astra Zeneca, Medtronic, Johnson & Johnson, Kimberly-Clark, Merck & Co, Pfizer Inc., Roche, Siemens and others.

Acquisitions/Product Launches

  • In October 2017, Abbott’s worldwide diagnostics business, sales growth over the last three years reflected the acquisition of Alere.
  • On December 2017, BD completed the acquisition of Bard, a global medical technology company in the fields of vascular, urology, oncology and surgical speciality products.

Post a comment

0 Comments